Malignant Pleural Effusion - Pipeline Insight, 2024

This “Malignant Pleural Effusion - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Malignant Pleural Effusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malignant Pleural Effusion: Understanding

Malignant Pleural Effusion: Overview

A malignant pleural effusion (MPE) is the buildup of fluid and cancer cells that collects between the chest wall and the lung. This can cause to feel short of breath and/or have chest discomfort. It is a fairly common complication in a number of different cancers. An MPE forms when cells from either a lung cancer or another type of cancer spread to the pleural space. These cancer cells increase the production of pleural fluid and cause decreased absorption of the fluid. People with lung cancer, breast cancer, and lymphoma (a cancer of lymphatic tissue) are most likely to get a MPE. Mesothelioma (a rare cancer of the pleura itself) is another common cause of MPE. Other causes of MPE include cancer that has spread from the stomach, kidney, ovaries, and colon. The symptoms of a MPE can be extremely variable and range from having no symptoms in some people to being very bothersome in others. Common symptoms: Shortness of breath at rest or with activity, chest pain or pressure, cough, pain when taking a deep breath, or the feeling of not being able to take a deep, satisfying breath, fever and Fatigue. Healthcare provider may first suspect that person has MPE on physical examination. To see if the person have MPE and estimate how much fluid is present, patient will have one or more of the imaging tests: Chest X-Ray: A picture showing a view of the chest, including the heart and lungs, CT Scan of the Chest: Multiple pictures of the chest that gives a lot more detail and information than a chest X-ray, Ultrasound of the Chest: One of the best methods of imaging the pleural space. Ultrasound does not involve any radiation and can also be used to help guide procedures to sample or drain pleural fluid. Medical oncologists (specialists who treat cancer) and radiation oncologists may treat the underlying cancer with chemotherapy, immunotherapy and/or radiation to prevent the fluid from accumulating.

Malignant Pleural Effusion - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Pleural Effusion pipeline landscape is provided which includes the disease overview and Malignant Pleural Effusion treatment guidelines. The assessment part of the report embraces, in depth Malignant Pleural Effusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant Pleural Effusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Malignant Pleural Effusion R&D. The therapies under development are focused on novel approaches to treat/improve Malignant Pleural Effusion.

Malignant Pleural Effusion Emerging Drugs Chapters

This segment of the Malignant Pleural Effusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant Pleural Effusion Emerging Drugs

LEITP-1009: LIPAC OncologyLIPAC is developing a new Liposomal Enhanced IntraThoracic Paclitaxel (LEITP) for the treatment of MPM utilizing the LiPax technology. Currently, the drug is being developed in the Pre-Clinical stage of clinical trial evaluation for the treatment of Malignant Pleural Effusion.

RSO-021: RS OncologyRSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. RSO-021 therapy has proven to significantly reduce pre-clinically tumor burden in malignant mesothelioma and other cancer types by inhibiting three key enzymes in the antioxidant signaling network within the mitochondria. Covalent adduction of the active site of a key mitochondrial enzyme by RSO-021 inactivates the peroxidase activity of the enzymes leading to accumulation of hydrogen peroxide to levels incompatible with tumor cell survival, while preserving healthy normal cells. RSO-021 is being developed for the treatment of malignant pleural effusion (MPE) via intrapleural (IP) installation in patients suffering from mesothelioma, breast cancer and other indications causing MPE.

SCB-313: Clover BiopharmaceuticalsSCB-313, has been designed and developed utilizing the Trimer-Tag™ technology platform. SCB-313 is a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. SCB-313 has the potential to address the unmet global need for the treatment of intracavitary malignancies, including Malignant Ascites (MA), Malignant Pleural effusions (MPE), and Peritoneal carcinomatosis (PC), as well as additional cancer indications.

Malignant Pleural Effusion: Therapeutic Assessment

This segment of the report provides insights about the different Malignant Pleural Effusion drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Malignant Pleural Effusion

There are approx. 8+ key companies which are developing the therapies for Malignant Pleural Effusion. The companies which have their Malignant Pleural Effusion drug candidates in the most advanced stage, i.e. phase I /II include, RS Oncology.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Malignant Pleural Effusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant Pleural Effusion: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant Pleural Effusion therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Pleural Effusion drugs.

Malignant Pleural Effusion Report Insights

• Malignant Pleural Effusion Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malignant Pleural Effusion Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malignant Pleural Effusion drugs?
• How many Malignant Pleural Effusion drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Pleural Effusion?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant Pleural Effusion therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant Pleural Effusion and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• LIPAC Oncology
• RS Oncology
• Clover Biopharmaceuticals
• Gongwin Biopharm Holdings
• Simcere Pharmaceutical Group

Key Products

• LEITP-1009
• RSO-021
• SCB-313
• PTS500
• ENDOSTAR

This product will be delivered within 2 business days.